Prognostic Impact of IDH Mutational Status in AML After HSCT
Posted: Friday, March 19, 2021
IDH mutation status did not seem to affect overall survival in patients with acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HSCT), according to a small single-center study. Eduardo Edelman Saul, MD, of Jackson Memorial Hospital, Miami, and colleagues presented their results at the 2021 Transplantation & Cellular Therapy Meetings (Abstract 155).
“Other disease characteristics, such as treatment-related AML and complete remission status, appear to influence outcomes,” the authors wrote.
The authors analyzed 62 patients with AML who underwent HSCT between 2012 and 2019. All patients were in complete morphologic remission, and 32% of patients had IDH mutations.
The median follow-up was 2.8 years. IDH mutation status did not affect 2-year overall survival or 2-year leukemia-free survival. The 2-year overall survival rates were 55% for patients with wild-type disease and 50% for patients with IDH mutations; the 2-year leukemia-free survival rates were 52% for patients with wild-type disease and 45% for patients with IDH mutations, with no statistical significance to the differences.
“HSCT beyond first complete remission and treatment-related AML resulted in inferior overall survival on univariate analysis (hazard ratios = 2.95 and 9.93, respectively; P < .01),” the authors reported. “Treatment-related AML also resulted in inferior leukemia-free survival on univariate analysis (hazard ratio = 14.3; P < .01) for all patients.” The authors noted that the effect of IDH mutations on outcomes after HSCT should be studied in larger cohorts.
Disclosure: The study authors’ disclosures may be found at tct.confex.com.